blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3679062

EP3679062 - T CELL RECEPTORS THAT BIND TO MIXED LINEAGE LEUKEMIA (MLL)-SPECIFIC PHOSPHOPEPTIDES AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusGrant of patent is intended
Status updated on  25.02.2024
Database last updated on 22.08.2024
FormerExamination is in progress
Status updated on  12.01.2024
FormerGrant of patent is intended
Status updated on  12.06.2023
FormerExamination is in progress
Status updated on  14.05.2021
FormerRequest for examination was made
Status updated on  12.06.2020
FormerThe international publication has been made
Status updated on  08.03.2019
Formerunknown
Status updated on  15.10.2018
Most recent event   Tooltip18.07.2024New entry: Application deemed to be withdrawn: despatch of communication + time limit 
Applicant(s)For all designated states
MiNK Therapeutics, Inc.
149 Fifth Avenue, Suite 500
New York, NY 10010 / US
[2023/43]
Former [2020/29]For all designated states
Agenus Inc.
3 Forbes Road
Lexington, MA 02421 / US
Inventor(s)01 / VAN DIJK, Marc
Tolhuislaan 8A
3735 KG Bosch en Duin / NL
02 / BREOUS-NYSTROM, Ekaterina Vladimirovna
Waldenburgerstrasse 15
4052 Basel / CH
03 / FRANCHINO, Alessandra
Luzernerring 124
4056 Basel / CH
04 / LALEVÉE, Sébastien
5 Rue des Cerisiers
68300 Saint Louis / FR
05 / HURWITZ, Arthur Andrew
9 Fitchdale Avenue
Bedford Massachusetts 01730 / US
06 / EXLEY, Mark Adrian
201 Reservoir Road
Chestnut Hill MA 02467 / US
07 / WOLF, Benjamin Jacob
478 Jamaicaway B
Boston MA 02130 / US
 [2020/29]
Representative(s)Simmons & Simmons LLP (Munich), et al
Lehel Carré
Thierschplatz 6
80538 Munich / DE
[N/P]
Former [2020/29]Lahrtz, Fritz
Patentanwälte
Isenbruck Bösl Hörschler PartG mbB
Prinzregentenstraße 68
81675 München / DE
Application number, filing date18782236.604.09.2018
[2020/29]
WO2018US49397
Priority number, dateUS201762553957P04.09.2017         Original published format: US 201762553957 P
[2020/29]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019046856
Date:07.03.2019
Language:EN
[2019/10]
Type: A1 Application with search report 
No.:EP3679062
Date:15.07.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 07.03.2019 takes the place of the publication of the European patent application.
[2020/29]
Search report(s)International search report - published on:EP07.03.2019
ClassificationIPC:A61K38/00, A61K45/06, A61P35/00, C07K14/705, C07K14/725, C12N9/10
[2023/24]
CPC:
C07K14/7051 (EP,KR,US); C12N5/0636 (KR); A61K38/00 (EP,KR,US);
A61K45/06 (EP,KR,US); A61P35/00 (EP,KR); C07K14/70503 (EP,KR);
C12N15/63 (US); C12N9/1007 (EP,KR); C12Y201/01008 (KR);
C07K2317/565 (US); C12N2510/00 (KR) (-)
Former IPC [2020/29]C07K14/705, C07K14/47
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/29]
Extension statesBA03.04.2020
ME03.04.2020
Validation statesKH03.04.2020
MA03.04.2020
MD03.04.2020
TN03.04.2020
TitleGerman:T-ZELL-REZEPTOREN, DIE AN MIXED LINEAGE LEUKEMIA(MLL)-SPEZIFISCHE PHOSPHOPEPTIDE BINDEN, UND VERFAHREN ZUR VERWENDUNG DAVON[2020/29]
English:T CELL RECEPTORS THAT BIND TO MIXED LINEAGE LEUKEMIA (MLL)-SPECIFIC PHOSPHOPEPTIDES AND METHODS OF USE THEREOF[2020/29]
French:RÉCEPTEURS DE LYMPHOCYTES T QUI SE LIENT À DES PHOSPHOPEPTIDES SPÉCIFIQUES DE LA LEUCÉMIE DE LIGNÉE MIXTE (MLL) ET MÉTHODES D'UTILISATION DE CES DERNIERS[2020/29]
Entry into regional phase03.04.2020National basic fee paid 
03.04.2020Designation fee(s) paid 
03.04.2020Examination fee paid 
Examination procedure03.04.2020Examination requested  [2020/29]
03.04.2020Date on which the examining division has become responsible
27.01.2021Amendment by applicant (claims and/or description)
17.05.2021Despatch of a communication from the examining division (Time limit: M06)
28.02.2022Reply to a communication from the examining division
16.08.2022Despatch of a communication from the examining division (Time limit: M04)
23.12.2022Reply to a communication from the examining division
13.06.2023Communication of intention to grant the patent
12.01.2024Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
26.02.2024Communication of intention to grant the patent
17.07.2024Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
12.01.2024Request for further processing filed
12.01.2024Full payment received (date of receipt of payment)
Request granted
22.01.2024Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
28.02.2022Request for further processing filed
28.02.2022Full payment received (date of receipt of payment)
Request granted
09.03.2022Decision despatched
27.01.2021Request for further processing filed
27.01.2021Full payment received (date of receipt of payment)
Request granted
03.02.2021Decision despatched
Fees paidRenewal fee
30.03.2021Renewal fee patent year 03
27.09.2021Renewal fee patent year 04
27.09.2022Renewal fee patent year 05
27.09.2023Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
30.09.202003   M06   Fee paid on   30.03.2021
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[IY]WO2011149909  (HUNT DONALD F [US], et al) [I] 1-170 * table 2B; sequences 166, 229 * * paragraph [0047] * * example 1 * [Y] 1-170;
 [Y]WO2017044672  (AGENUS INC [US]) [Y] 1-170 * examples 3, 5, 6 * * paragraph [0059] *;
 [Y]  - M. COBBOLD ET AL, "MHC Class I-Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia", SCIENCE TRANSLATIONAL MEDICINE, US, (20130918), vol. 5, no. 203, doi:10.1126/scitranslmed.3006061, ISSN 1946-6234, pages 203ra125 - 203ra125, XP055532798 [Y] 1-170 * the whole document * * figures 4a, c, e *

DOI:   http://dx.doi.org/10.1126/scitranslmed.3006061
    [ ] - M. COBBOLD ET AL, "MHC Class I-Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia", SCIENCE TRANSLATIONAL MEDICINE, US, (20130918), vol. 5, no. 203, doi:10.1126/scitranslmed.3006061, ISSN 1946-6234, pages 203ra125 - 203ra125, XP055532847 [ ] * the whole document * * figures S2, S3, S6 *

DOI:   http://dx.doi.org/10.1126/scitranslmed.3006061
 [XP]  - C. Plewa ET AL, "Discovery of phospho-peptide neoantigen tumor targets (PTTs) and identification of novel T cell receptors (TCRs) targeting phospho-MLL for adoptive cell therapy AgenTus Therapeutics: differentiated cell therapy", (20180831), URL: http://www.agentustherapeutics.com/wp-content/uploads/2018/09/AgenTus-PTT_MLL-Poster-2018_0831-FINAL.pdf, (20181211), XP055532797 [XP] 1-170 * the whole document *
by applicantDE1370147
 WO9618105
 US5580714
 US5807715
 US5965726
 WO9957268
 WO0031239
 US6174666
 US6291664
 US6383492
 US6391306
 US6403095
 US6410026
 US6414132
 US6436404
 US6447780
 US6447781
 WO03020763
 US6610659
 US6645495
 US2003232323
 US2004014194
 WO2004033685
 US6740484
 US6794498
 US6808710
 US2005048549
 US7029678
 US7052906
 US7329731
 US7332582
 US7488802
 WO2010005958
 US2010203056
 US7858589
 WO2011044186
 US7943743
 US8008449
 US8114845
 US8168757
 US8168179
 US8217149
 US8354509
 US8361794
 WO2013033091
 US2013202623
 WO2013126712
 US8552154
 US2013291136
 US2013323249
 WO2014022758
 US2014044738
 US8686119
 WO2014055897
 US8735553
 US8747847
 WO2014100079
 US8779105
 US8779108
 WO2014179664
 US2014341917
 US2014356363
 US8906383
 WO2014209804
 WO2014206107
 US8927697
 US8981063
 WO2015036394
 US8993731
 WO2015058573
 WO2015061668
 WO2015085847
 US2015203580
 WO2015109124
 US9089520
 US9102727
 US2015225483
 WO2015123527
 US9175082
 US2015346208
 US9205148
 US2015355184
 WO2015195163
 WO2015200119
 WO2016000619
 WO2016015685
 WO2016020856
 WO2016030350
 US2016075783
    - COBBOLD et al., Sci Transl Med., (20130918), vol. 5, no. 203, page 203ral25
    - LEFRANC, The Immunologist, (19990000), vol. 7, pages 132 - 136
    - LEFRANC et al., Nucleic Acids Res, (19990000), vol. 27, pages 209 - 212
    - LEFRANC et al., Dev Comp Immunol., (20030000), vol. 27, no. l, pages 55 - 77
    - SAVAGE et al., Immunity, (19990000), vol. 10, no. 4, pages 485 - 492
    - GIEGE R et al., Acta Crystallogr D Biol Crystallogr, (19940000), vol. 50, pages 339 - 350
    - MCPHERSON A, Eur J Biochem, (19900000), vol. 189, pages 1 - 23
    - CHAYEN NE, Structure, (19970000), vol. 5, pages 1269 - 1274
    - MCPHERSON A, J Biol Chem, (19760000), vol. 251, pages 6300 - 6303
    - Meth Enzymol, (19850000), vol. 114-115
    - BRICOGNE G, Acta Crystallogr D Biol Crystallogr, (19930000), vol. 49, pages 37 - 60
    - BRICOGNE G, Meth Enzymol, (19970000), vol. 276A, pages 361 - 423
    - Acta Crystallogr D Biol Crystallogr, (20000000), vol. 56, pages 1316 - 1323
    - CHAMPE M et al., J Biol Chem, (19950000), vol. 270, pages 1388 - 1394
    - CUNNINGHAM BC; WELLS JA, Science, (19890000), vol. 244, pages 1081 - 1085
    - KARLIN S; ALTSCHUL S, PNAS, (19900000), vol. 87, pages 2264 - 2268
    - KARLIN S; ALTSCHUL SF, PNAS, (19930000), vol. 90, pages 5873 - 5877
    - ALTSCHUL SF et al., J Mol Biol, (19900000), vol. 215, page 403
    - ALTSCHUL SF et al., Nuc Acids Res, (19970000), vol. 25, pages 3389 - 3402
    - MYERS; MILLER, CABIOS, (19880000), vol. 4, pages 11 - 17
    - KOPYTEK, S J. et al., Chemistry & Biology, (20000000), vol. 7, pages 313 - 321
    - GESTWICKI, J. E. et al., Combinatorial Chem. & High Throughput Screening, (20070000), vol. 10, pages 667 - 675
    - CLACKSON T, Chem Biol Drug Des, (20060000), vol. 67, pages 440 - 442
    - COBBOLD et al., Sci Transl Med., (20130918), vol. 5, no. 203, page 203ra125
    - RAO et al., Nat Rev Cancer, (20150600), vol. t5, no. 6, pages 334 - 346
    - LI et al., Exp Hematol., (20141200), vol. 42, no. 12, pages 995 - 1012
    - KRIVTSOV et al., Nat Rev Cancer, (20071100), vol. 7, no. 11, pages 823 - 833
    - DWORNICZAK; MIRAULT, Nucleic Acids Res., (19870000), vol. 15, pages 5181 - 5197
    - "GenBank", Database accession no. P11142
    - HUNT; MORIMOTO, Proc. Natl. Acad. Sci. U.S.A., (19850000), vol. 82, no. 19, pages 6455 - 6459
    - "GenBank", Database accession no. PODMV8
    - "GenBank", Database accession no. Ml 1717
    - KUTMEIER G et al., BioTechniques, (19940000), vol. 17, pages 242 - 246
    - Current Protocols in Molecular Biology, Green Publishing Associates. Inc. and John Wiley & Sons, Inc., (19890000), vol. I, pages 6.3.1 - 6.3.6
    - FOCCKING MK; HOFSTETTER H, Gene, (19860000), vol. 45, pages 101 - 105
    - COCKETT MI et al., Biotechnology, (19900000), vol. 8, no. 7, pages 662 - 667
    - RUETHER U; MUELLER-HILL B, EMBO J, (19830000), vol. 2, pages 1791 - 1794
    - INOUYE S; INOUYE M, Nuc Acids Res, (19850000), vol. 13, pages 3101 - 3109
    - VAN HEEKE G; SCHUSTER SM, J Biol Chem, (19890000), vol. 24, pages 5503 - 5509
    - LOGAN J; SHENK T, PNAS, (19840000), vol. 81, no. 12, pages 3655 - 3659
    - BITTER G et al., Methods Enzymol., (19870000), vol. 153, pages 516 - 544
    - WIGLER M et al., Cell, (19770000), vol. 11, no. 1, pages 223 - 232
    - SZYBALSKA EH; SZYBALSKI W, PNAS, (19620000), vol. 48, no. 12, pages 2026 - 2034
    - LOWY I et al., Cell, (19800000), vol. 22, no. 3, pages 817 - 823
    - WIGLER M et al., PNAS, (19800000), vol. 77, no. 6, pages 3567 - 3570
    - O'HARE K et al., PNAS, (19810000), vol. 78, pages 1527 - 1531
    - MULLIGAN RC; BERG P, PNAS, (19810000), vol. 78, no. 4, pages 2072 - 2076
    - WU GY; WU CH, Biotherapy, (19910000), vol. 3, pages 87 - 95
    - TOLSTOSHEV P, Ann Rev Pharmacol Toxicol, (19930000), vol. 32, pages 573 - 596
    - MULLIGAN RC, Science, (19930000), vol. 260, pages 926 - 932
    - MORGAN RA; ANDERSON WF, Ann Rev Biocheni, (19930000), vol. 62, pages 191 - 217
    - NABEL GJ; FEIGNER PL, Trends Biotechnol, (19930000), vol. 11, no. 5, pages 211 - 215
    - SANTERRE RF et al., Gene, (19840000), vol. 30, no. 1-3, pages 147 - 156
    - COLBERE-GARAPIN F et al., J Mol Biol, (19810000), vol. 150, pages 1 - 114
    - BEBBINGTON CR; HENTSCHEL CCG, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Academic Press, (19870000), vol. 3
    - CROUSE GF et al., Mol Cell Biol, (19830000), vol. 3, pages 257 - 266
    - ZHAO Y, J Immunol, (20070000), vol. 179, pages 5845 - 5854
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.